ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals discloses a 2026 stock sale by former officer John Militello, detailing amounts, tax use and compliance to keep investors informed.

Rocket Pharmaceuticals’ May 13, 2026 Form 4 filings show executive RSU sales and ongoing stakes, highlighting the company’s gene‑therapy focus and steady management commitment.

Rocket Pharmaceuticals’ gene‑therapy focus fuels a 14.3% rally, but a negative P/E and R&D costs underline investor risk and future growth potential.

Rocket Pharmaceuticals is pushing gene‑therapy breakthroughs for rare pediatric diseases, trading around $4, with a 52‑week high of $9.84, a P/B of 1.30, and investor‑focused engagements at major healthcare conferences.

Rocket Pharmaceuticals is making strides in gene therapy development, presenting promising preliminary data from a Phase 1 clinical trial and solidifying its position as a leader in the biotechnology sector.

Rocket Pharmaceuticals, Inc. is a pioneering biotech company dedicated to developing gene therapies for rare and catastrophic pediatric diseases, offering hope to patients and families worldwide.

Rocket Pharmaceuticals Inc.’s stock has experienced significant volatility, with recent insider buying activity sparking interest, but the company’s future remains uncertain due to the high risks and challenges in the biotech sector.

Rocket Pharmaceuticals Inc. is facing significant financial and operational challenges, with its stock price plummeting from $26.98 to $8.32, as the company navigates the high-risk, high-reward world of biotech gene therapies.